CL2008003527A1 - Conjugado de anticuerpo o porcion de union de antigeno del mismo, que se une a la proteina tirosina quinasa 7 (ptk-7/cck4); composicion que lo comprende; acido nulceico cidificante del anticuerpo; vector y celula huesped; uso del conjugado para tratar o prevenir una enfermedad de celulas tumorales que expresan ptk7 - Google Patents
Conjugado de anticuerpo o porcion de union de antigeno del mismo, que se une a la proteina tirosina quinasa 7 (ptk-7/cck4); composicion que lo comprende; acido nulceico cidificante del anticuerpo; vector y celula huesped; uso del conjugado para tratar o prevenir una enfermedad de celulas tumorales que expresan ptk7Info
- Publication number
- CL2008003527A1 CL2008003527A1 CL2008003527A CL2008003527A CL2008003527A1 CL 2008003527 A1 CL2008003527 A1 CL 2008003527A1 CL 2008003527 A CL2008003527 A CL 2008003527A CL 2008003527 A CL2008003527 A CL 2008003527A CL 2008003527 A1 CL2008003527 A1 CL 2008003527A1
- Authority
- CL
- Chile
- Prior art keywords
- antibody
- conjugate
- vector
- binds
- tumor cells
- Prior art date
Links
- 102100039813 Inactive tyrosine-protein kinase 7 Human genes 0.000 title abstract 2
- 101710099452 Inactive tyrosine-protein kinase 7 Proteins 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 title abstract 2
- 210000004881 tumor cell Anatomy 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229940127121 immunoconjugate Drugs 0.000 title 1
- RGYLYUZOGHTBRF-BIHRQFPBSA-N tetragastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)CCSC)C(N)=O)C1=CC=CC=C1 RGYLYUZOGHTBRF-BIHRQFPBSA-N 0.000 title 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US503407P | 2007-11-30 | 2007-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2008003527A1 true CL2008003527A1 (es) | 2009-10-09 |
Family
ID=40718460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2008003527A CL2008003527A1 (es) | 2007-11-30 | 2008-11-26 | Conjugado de anticuerpo o porcion de union de antigeno del mismo, que se une a la proteina tirosina quinasa 7 (ptk-7/cck4); composicion que lo comprende; acido nulceico cidificante del anticuerpo; vector y celula huesped; uso del conjugado para tratar o prevenir una enfermedad de celulas tumorales que expresan ptk7 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20120027782A1 (enExample) |
| EP (1) | EP2229187A2 (enExample) |
| JP (1) | JP2011505146A (enExample) |
| KR (1) | KR20100101124A (enExample) |
| CN (1) | CN101939028A (enExample) |
| AR (1) | AR069903A1 (enExample) |
| AU (1) | AU2008334076A1 (enExample) |
| CL (1) | CL2008003527A1 (enExample) |
| MX (1) | MX2010005966A (enExample) |
| TW (1) | TW200938223A (enExample) |
| WO (1) | WO2009073546A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006321841C1 (en) | 2005-12-08 | 2013-01-24 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to protein tyrosine kinase 7 ( PTK7 ) and their use |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| MX2011004625A (es) | 2008-11-03 | 2011-07-20 | Syntarga Bv | Analogos cc-1065 novedosos y sus conjugados. |
| CA2956934C (en) | 2010-04-21 | 2019-07-09 | Syntarga B.V. | Novel conjugates of cc-1065 analogs and bifunctional linkers |
| EP2380909A1 (en) * | 2010-04-26 | 2011-10-26 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | PTK-7 protein involved in breast cancer |
| SA112330278B1 (ar) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | مواد ضابطة جديدة وطرق للاستخدام |
| US8852599B2 (en) | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
| WO2013024049A1 (en) * | 2011-08-12 | 2013-02-21 | Ascendis Pharma A/S | Protein carrier-linked prodrugs |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| WO2015095755A1 (en) * | 2013-12-19 | 2015-06-25 | Seattle Genetics, Inc. | Methylene carbamate linkers for use with targeted-drug conjugates |
| AU2015205574B2 (en) | 2014-01-10 | 2019-08-15 | Byondis B.V. | Method for purifying Cys-linked antibody-drug conjugates |
| EP3137114B8 (en) | 2014-04-30 | 2021-08-04 | Pfizer Inc. | Anti-ptk7 antibody-drug conjugates |
| AU2015271709B2 (en) | 2014-06-06 | 2020-11-26 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof |
| PL3221346T3 (pl) | 2014-11-21 | 2021-03-08 | Bristol-Myers Squibb Company | Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego |
| TWI711630B (zh) | 2014-11-21 | 2020-12-01 | 美商必治妥美雅史谷比公司 | 抗ｃｄ７３抗體及其用途 |
| MY187045A (en) | 2014-12-23 | 2021-08-27 | Bristol Myers Squibb Co | Antibodies to tigit |
| CA3005855A1 (en) | 2015-11-19 | 2017-05-26 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
| CA3016187A1 (en) | 2016-03-04 | 2017-09-08 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
| EA201991720A1 (ru) | 2017-02-17 | 2020-01-20 | Бристол-Маерс Сквибб Компани | Антитела к альфа-синуклеину и их применения |
| CN110869392A (zh) | 2017-05-16 | 2020-03-06 | 百时美施贵宝公司 | 用抗gitr激动性抗体治疗癌症 |
| US20200299400A1 (en) | 2017-05-25 | 2020-09-24 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| WO2020094670A1 (en) | 2018-11-05 | 2020-05-14 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing trop-2 |
| CN110845480B (zh) * | 2019-11-22 | 2022-03-15 | 荣昌生物制药(烟台)股份有限公司 | 一种双功能细胞毒素及其用途 |
| US12605433B2 (en) | 2020-07-16 | 2026-04-21 | Uif (University Industry Foundation), Yonsei University | Antibody specifically binding to PTK7 and use thereof |
| CN115894696A (zh) * | 2021-08-18 | 2023-04-04 | 和迈生物科技有限公司 | 抗ptk7单域抗体及其应用 |
| IL315366A (en) | 2022-03-23 | 2024-11-01 | Synaffix Bv | Antibody pairs for targeting PTK7-expressing tumors |
| GB202212077D0 (en) | 2022-08-18 | 2022-10-05 | Tribune Therapeutics Ab | Agents that inhibit ccn ligand-induced signalling for treating disease |
| WO2024054030A1 (ko) * | 2022-09-06 | 2024-03-14 | 연세대학교 산학협력단 | 항-ptk7 항체 및 이의 용도 |
| CN118852442A (zh) * | 2023-04-26 | 2024-10-29 | 上海麦科思生物医药有限公司 | 抗ptk7抗体及其用途 |
| WO2025040588A1 (en) * | 2023-08-18 | 2025-02-27 | Oncoinvent As | Monoclonal anti-ptk7 antibodies and derivatives |
| WO2025072406A1 (en) * | 2023-09-26 | 2025-04-03 | Profoundbio Us Co. | Ptk7 binding agents, conjugates thereof and methods of using the same |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1423110A4 (en) * | 2001-09-07 | 2005-04-27 | Scripps Research Inst | CBI ANALOGUE OF CC-1065 AND DUOCARMYCINES |
| GB0219776D0 (en) * | 2002-08-24 | 2002-10-02 | Oxford Glycosciences Uk Ltd | A protein involved in carcinoma |
| US7691962B2 (en) * | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
| US7517903B2 (en) * | 2004-05-19 | 2009-04-14 | Medarex, Inc. | Cytotoxic compounds and conjugates |
| AU2006294554B2 (en) * | 2005-09-26 | 2013-03-21 | E. R. Squibb & Sons, L.L.C. | Antibody-drug conjugates and methods of use |
| AU2006321841C1 (en) * | 2005-12-08 | 2013-01-24 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to protein tyrosine kinase 7 ( PTK7 ) and their use |
-
2008
- 2008-11-26 AR ARP080105143A patent/AR069903A1/es not_active Application Discontinuation
- 2008-11-26 EP EP08857264A patent/EP2229187A2/en not_active Withdrawn
- 2008-11-26 CL CL2008003527A patent/CL2008003527A1/es unknown
- 2008-11-26 US US12/745,503 patent/US20120027782A1/en not_active Abandoned
- 2008-11-26 CN CN200880118641XA patent/CN101939028A/zh active Pending
- 2008-11-26 KR KR1020107014503A patent/KR20100101124A/ko not_active Withdrawn
- 2008-11-26 JP JP2010536185A patent/JP2011505146A/ja not_active Withdrawn
- 2008-11-26 AU AU2008334076A patent/AU2008334076A1/en not_active Abandoned
- 2008-11-26 TW TW097145713A patent/TW200938223A/zh unknown
- 2008-11-26 MX MX2010005966A patent/MX2010005966A/es not_active Application Discontinuation
- 2008-11-26 WO PCT/US2008/084949 patent/WO2009073546A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009073546A3 (en) | 2009-12-30 |
| EP2229187A2 (en) | 2010-09-22 |
| WO2009073546A2 (en) | 2009-06-11 |
| MX2010005966A (es) | 2010-06-15 |
| JP2011505146A (ja) | 2011-02-24 |
| CN101939028A (zh) | 2011-01-05 |
| AR069903A1 (es) | 2010-03-03 |
| AU2008334076A1 (en) | 2009-06-11 |
| US20120027782A1 (en) | 2012-02-02 |
| TW200938223A (en) | 2009-09-16 |
| KR20100101124A (ko) | 2010-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123030T1 (el) | Υλικο και μεθοδοι για θεραπεια ή αποτροπη σχετικων me her-3 ασθενειων | |
| ES2542853T3 (es) | Método para tratar miastenia grave | |
| ES2525477T3 (es) | Anticuerpos anti-factor D humanizados | |
| ES2540858T3 (es) | Composición farmacéutica para el tratamiento y/o la prevención de cáncer | |
| MX2021014952A (es) | Molecula de union especifica para cd73 y uso de la molecula de union. | |
| MX2010005966A (es) | Conjugados de anticuerpo monoclonal-molecula asociada dirigidos a la proteina tirosina-cinasa 7 (ptk7). | |
| AR074360A1 (es) | Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| CL2011000230A1 (es) | Anticuerpo monoclonal humano aislado que se une al inhibidor de la via del factor tisular (tfpi); composicion farmaceutica que lo comprende; uso para tratar deficiencias adquiridas o geneticas de la coagulacion, o para acortar el tiempo de sangrado. | |
| MX2020004578A (es) | Composiciones de casz y metodos de uso. | |
| NI200900022A (es) | Anticuerpo especifico de prlr y usos del mismo | |
| CL2007003649A1 (es) | Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70. | |
| EA200970737A1 (ru) | Оксабициклогептаны и оксабициклогептены, их получение и применение | |
| CL2011001382A1 (es) | Anticuerpo o fragmento de union a antigeno especifico para el ligando 1 de muerte programada (pd-li); acido nucleico que lo codifica; vector; celula huesped; proceso de produccion; composicion que lo comprende; y su uso para tratar un trastorno disfuncional de celulas t. | |
| AR080663A1 (es) | Proteinas de union especificas y sus usos | |
| AR109355A2 (es) | Moléculas de unión al receptor ox40 humano | |
| PE20120902A1 (es) | Anticuerpos anti-egfl7 humanizados | |
| PE20091713A1 (es) | Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos | |
| CL2008003784A1 (es) | Anticuerpo humanizado anti proteina e2 del virus de la hepatitis c o un fragmento de union; acido nucleico que lo codifica; vector y celula huesped que comprenden dicho acido nucleico; metodo para producir el anticuerpo; composicion farmaceutica que comprende el anticuerpo | |
| AR075896A1 (es) | Anticuerpos anti-her (factor de crecimiento epidermico) | |
| EA201900561A1 (ru) | Конъюгаты циклодекстрин-белок-лекарственное средство | |
| PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
| CL2012000229A1 (es) | Anticuerpo humano aislado o un fragmento del mismo de unión al antígeno, que se une específicamente a la angiopoyetina-2 humana (hang-2) pero que no se une sustancialmente a la hang-1; composición farmacéutica que lo comprende; y su uso para el tratamiento de un tumor, hipertensión, diabetes, edema, enfermedad renal u ocular. | |
| CR10147A (es) | "ligandos que tienen especificidad de enlace para vegf y/o egfr y métodos de uso de los mismos" | |
| CY1116970T1 (el) | Fkbp-l και χρησεις αυτων ως αναστολεις αγγειογενεσης |